Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by VG Serpik
Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pcn90 - Cost-Effectiveness and Budget Impact Analysis of Nilotinib for the Second Line Tratment of Chronic Mieloid Leukemia in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Satisfaction With Information on Nilotinib Treatment in Chronic Myeloid Leukemia Patients
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
Pharmacoeconomic Analysis of Dasatinib as a Second-Line Therapy in Patients With Chronic Myelogenous Leukemia
Pharmacoeconomics: theory and practice
Nilotinib for the Treatment of Chronic Myeloid Leukemia: An Evidence-Based Review
Core Evidence
Medicine
Reviews
References
Pharmacology
Development of Myasthenia Gravis in a Patient With Chronic Myeloid Leukemia During Treatment With Nilotinib
Hematology Reports
Hematology
Rates of Peripheral Arterial Occlusive Disease in Patients With Chronic Myeloid Leukemia in the Chronic Phase Treated With Imatinib, Nilotinib, or Non-Tyrosine Kinase Therapy: A Retrospective Cohort Analysis
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Budget Impact Analysis of Formoterol Easyhaler in the Treatment of Asthma in Children in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PSY12 the Cost of Treating Chronic Myeloid Leukemia (CML) in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
